Indian Journal of Obstetrics and Gynecology Research


STUDY OF INTRAVENOUS FERRIC CARBOXY MALTOSE IN IRON DEFICIENCY ANEMIA DURING PREGNANCY AND POST- PARTUM PERIOD- SAFETY AND EFFICACY


Full Text PDF



Author Details: V V Mishra, Sumesh Chaudhary, Khushali Gandhi, Urmila Sharma, Ushma Patel

Volume : 2

Issue : 2

Online ISSN : 2394-2754

Print ISSN : 2394-2746

Article First Page : 69

Article End Page : 72


Abstract

Background and objectives: Iron deficiency is common among women of childbearing age in both the developed and developing countries. Intravenous Ferric carboxy maltose (FCM) is a novel molecule which can be safely administered in a single dose as large as 1000mg in as little as 15 minutes with no significant adverse effects.

Methods: A hospital based prospective study included 39 antenatal women >20-36 weeks gestation and 119 postpartum women with documented iron deficiency anemia. Intravenous Ferric carboxy maltose (FCM) was administered and improvement in hemoglobin and iron stores was assessed after 3 weeks. Safety of intravenous FCM was also assessed during the study.

Results: There was a significant improvement in hemoglobin over a period of 3 weeks from mean Hb 8.97±1.05 gm/dL to 11.34±0.90 gm/dL with p value <0.001 which was statistically significant. There was also a significant improvement in serum ferritin levels with p value <0.001. No serious adverse effects of FCM were noted in this study.

Conclusions: Intravenous FCM is effective in treatment of iron deficiency anemia without significant adverse effects in pregnancy after first trimester and during post-partum period. FCM should be offered to all women with IDA to minimize maternal morbidity & mortality.


Key words: Iron deficiency anaemia, Postpartum anaemia, Intravenous iron, Ferric carboxy maltose

Doi No:-10.18231